Published in Healthcare Mergers, Acquisitions and Ventures Week, November 13th, 2004
The Principal Group has routinely covered the nasal prescription and the injectable vaccine as standard practice.
The U.S. government announced the United States would receive only half of its expected supply of injectable vaccine. FluMist, a nasally inhaled flu vaccine, is an alternative to injection and is available via prescription. Consistent with U.S. Food and Drug Adaministration-approved indications for FluMist, the company will cover the nasal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.